Axsome Shares Up 20% in a Month: How Should You Play the Stock?

Axsome Therapeutics (AXSM) shares rallied 20.2% over the past month, primarily driven by robust sales of its lead major depressive disorder drug, Auvelity, which generated $215.9 million in H1 2025, an 82.3% year-over-year increase, alongside strong performance from narcolepsy drug Sunosi and the recent launch of migraine treatment Symbravo. The company is also pursuing label expansions for Auvelity into Alzheimer's agitation and smoking cessation, and advancing other CNS pipeline candidates. However, AXSM faces significant competition in its target markets and recently received a Refusal to File letter for its AXS-14 fibromyalgia candidate, while its valuation remains at a premium and 2025/2026 EPS estimates have deteriorated.

Analysis

Axsome Therapeutics (AXSM) has demonstrated significant commercial momentum, reflected in a 20.2% share price rally over the past month, which outpaced the broader industry's 2.5% rise. This performance is primarily anchored by its lead major depressive disorder drug, Auvelity, which saw first-half 2025 sales surge 82.3% year-over-year to $215.9 million, with models projecting a 42.7% CAGR for the next three years. The portfolio is further supported by the narcolepsy drug Sunosi, which grew 25.6% to $53 million in the same period, and the recent U.S. launch of the migraine treatment Symbravo. Key upcoming catalysts include a planned supplemental new drug application (sNDA) for Auvelity in Alzheimer's disease agitation in Q3 2025 and a new drug application (NDA) for AXS-12 for narcolepsy in Q4 2025. However, these positive developments are tempered by significant headwinds. The company faces a recent regulatory setback with the FDA's Refusal to File letter for its fibromyalgia candidate, AXS-14, highlighting pipeline execution risk. Furthermore, the stock trades at a premium price-to-sales ratio of 12.16 versus the industry's 2.12, and consensus earnings estimates have deteriorated, with the 2025 loss estimate widening to $3.41 per share and the 2026 EPS estimate declining to $0.92.

Key Decisions for Investors

• Investors should closely monitor Auvelity's sales trajectory and its upcoming sNDA submission for Alzheimer's agitation in Q3 2025, as this is the primary growth driver and a critical catalyst for justifying the stock's premium valuation.
• Exercise caution due to the stock's high valuation, indicated by a P/S ratio of 12.16, and the recent negative revisions to 2025 and 2026 earnings estimates, which suggest heightened vulnerability to any execution missteps or competitive pressures.
• Factor in the heightened regulatory risk following the Refusal to File letter for AXS-14, and closely watch for successful execution on other pipeline milestones, particularly the planned Q4 2025 NDA submission for AXS-12, as further setbacks could materially impact the stock.
• Given the mixed signals of strong revenue growth against a premium valuation and execution risks, a hold rating appears appropriate for existing positions, while prospective investors should await a more favorable entry point or positive resolution of key catalysts.